1Kessler RCA, Aguilar - Gaxiola S, Alonso J, et al. The global bur- den of mental disorders: an update from the WHO World Mental Health (WMH)surveys[J]. Epidemiol Psichiatr Soc,2009,18:23 -33.
6Nutt D. Management of patients with depression associated with anxiety symptoms. Clin Psychiatry, 1997 ;58 ( suppl. 8 ) : 11 -16.
7Owens M J, Knight DL, Nemeroff CB. Second - generation SS- RIs : human monoamine transporter binding profile of escitalo- pram and R - fluoxetine. Biol Psychiatry, 2001 ; 50 ( 5 ) : 345 - 350.
8Mmerman M. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry, 2000; 157(8) :1337 -40.
9De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine com- pared with fluoxetine in outpatients with depression and con- comitant anxiety. Int J Neuropsychopharmacol. 2002 ;5 (2) : 115 - 120.
10Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety, 2003 ; 18(2) :53 - 61.
